Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Cancer drug research may undergo a significant shift as scientists are not just studying what happens to a cell after treatment, but watch the process unfold in real time.

Indian-origin biotech entrepreneur Parmita Mishra is developing a live-cell technology that combines Raman spectroscopy, photonics, microfluidics and computational biology to continuously monitor living cells without fluorescent labels or destructive sample preparation.

The approach, described by the researchers as “live-cell cinema,” aims to address a longstanding problem in drug discovery: conventional laboratory techniques often provide snapshots of cellular behaviour rather than a continuous picture of how cells respond to treatment and other changes.

Mishra said, "Biology is constantly moving, yet for decades we have largely studied it through static snapshots. If we want to understand why cancer cells change, adapt or resist therapy, we need technologies that allow us to observe living biology continuously rather than after the fact. Our mission is to give researchers that capability."

Why This Could Be Game Changing In Cancer Drug Research?

Traditional experiments require cells to be fixed, stained, lysed or otherwise destroyed before researchers analyse them. Even studies that examine multiple time points may rely on different populations of cells at each stage of the research.

A recent Drug Discovery News report highlighted research that cancer cells can move through intermediate molecular states as they develop treatment resistance, suggesting that important biological changes may occur before resistance becomes obvious.

The idea behind live-cell examination is therefore simple: if biology changes continuously, why should scientists only measure it at the end?

Also read: Lung Health After 40: Natural Changes, Warning Signs And Ways To Protect Your Lungs

How Does The Technology Work?

Raman spectroscopy analyses how light interacts with molecules, producing chemical information without necessarily requiring dyes or labels.

Its system combines this optical technology with microfluidic chips that maintain cells under controlled conditions, including temperature, nutrients and carbon dioxide. This allows researchers to observe the same living cells as their biology changes.

Mishra said that artificial intelligence can process enormous amounts of information, but its utility in drug discovery depends on having better biological data to learn from.

Also read: Tudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice

How Could This Impact Cancer Drug Discovery?

By capturing biochemical changes continuously, technologies such as live-cell Raman imaging could potentially help researchers identify drug responses, toxicity or resistance earlier during preclinical testing.

Dr. Shyam Aggarwal , Chairperson, Department of Medical Oncology at Sir Ganga Ram Hospital, New Delhi said “Real-time observation technologies could help researchers better understand how cells respond to candidate drugs, monitor subtle biochemical changes earlier, and potentially identify promising therapies more efficiently during preclinical research. Understanding precision oncology with CGP comprehensive genome profiling and MRD minimal residual disease detection will help physicians improve targeted personised medicine for cancer patients. While such technologies are not themselves treatments, they may strengthen the scientific foundation on which future therapies are developed.”

For cancer research, that window could eventually help scientists understand not only whether a drug works, but how a living cancer cell changes while the drug is working.

Mishra further added "We are not trying to replace scientists or physicians—we are trying to give them a better window into living biology," "When researchers can continuously measure how cells behave instead of relying on biological 'autopsies,' they may uncover insights that were previously impossible to observe. That has implications far beyond cancer, extending into immunology, neuroscience, rare diseases and regenerative medicine. "For decades, we've been studying life after it has stopped.The future of biomedical research lies in understanding life while it is still unfolding."

However, the technology is still being developed and requires independent validation before its potential impact on drug discovery can be established.

Dr Rahul Bhargava, Principal Director of Hematology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram said “Cancer is an extraordinarily dynamic disease, and researchers around the world are exploring technologies that can better capture how living cells change over time. Innovations that enable continuous, non-invasive observation of cellular behavior could become valuable research tools for improving disease models and accelerating drug discovery. While clinical validation remains essential, this represents an exciting direction for biomedical science."

90s star Samuel Monroe Jr., best known for his role in the 1993 film Menace II Society, remains critically ill in a Los Angeles hospital. His family is now facing the possibility that he may end up in a vegetative state.

According to the latest update shared by his wife, Shawna Stewart, Monroe is in a medically induced coma and remains on life support.

Doctors have said that he could ultimately be left in that life state as complications in his brain continue to worsen.

What Happened To Samuel Monroe Jr.?

Samuel's health crisis reportedly began with meningitis. Stewart previously said he contracted the infection while filming in Las Vegas around 18 months before his hospitalization, but the illness was repeatedly misdiagnosed.

“Because of this negligence, the meningitis went untreated for eight months,” Stewart said. She also said that by the time it was diagnosed, the infection had spread to his spine and brain.

His condition later became more complicated after he developed MRSA pneumonia, a serious infection caused by methicillin-resistant Staphylococcus aureus. He needed life support, dialysis, and multiple blood transfusions for several months.

There was some improvement in his health in May. His kidney function improved enough for doctors to stop dialysis; he was taken off blood-pressure medication and was able to breathe without a ventilator for about four hours.

He was also reportedly alert and well enough to answer questions by moving his head. But that phase did not last.

Also read: Alex Hughes: Former Manchester United Star’s Son Dies of Sudden Adult Death Syndrome

What Does Vegetative State Mean?

A vegetative state is different from a coma, although both involve severe impairment of consciousness.

A person in a vegetative state may have periods of wakefulness, like opening their eyes, but may not show any sign of awareness of themselves or their surroundings. Basic functions like breathing and sleep-wake cycles can continue.

Importantly, doctors cannot determine an individual's neurological outcome from one symptom alone. The extent and location of brain injury, neurological examinations and repeated imaging, and other assessments are considered.

Also read: Donald Trump Mulls Order Targeting Childhood Vaccines And Autism

Samuel Monroe Jr's Family Faces A Challenging Decision

Stewart told TMZ that Monroe’s brain continues to swell and that his brain ventricles have enlarged and are struggling to properly contain cerebral fluid. The pressure and complications in his brain have triggered seizures.

Monroe has undergone three brain surgeries, while his left lung has also partially collapsed. Doctors are continuing to perform CT scans to assess his brain activity and condition.

Brain swelling is particularly dangerous as the skull is a rigid body part. When fluid or swelling increases inside it, pressure can rise and potentially damage brain tissue.

Severe or prolonged swelling can affect consciousness, movement, communication, and other essential neurological functions.

According to reports, Monroe’s family is not making an immediate decision about his life support.

Stewart said the family has agreed to wait for three or four more CT scans before making a decision. Depending on those scans, the family may have to take the decision of withdrawing life support.

In a major scientific breakthrough, researchers at Stanford University have used artificial intelligence (AI) to design entirely new viruses that do not exist in nature.

The AI-generated viruses successfully killed Escherichia coli (E. coli) bacteria that had become resistant to naturally occurring bacteriophages (phages)—viruses that infect and destroy bacteria—offering new hope for tackling antibiotic-resistant infections.

The study, published in the journal Science, also raises important biosafety concerns, as the same technology could potentially be misused to design harmful pathogens.

How AI Created the Viruses?

Chemical engineer Brian Hie and bioengineering graduate student Samuel King developed Evo 2, a generative AI model capable of writing complete DNA sequences and designing entirely new genomes.

The researchers focused on bacteriophages, viruses that infect bacteria and are already being explored as alternatives to antibiotics for treating difficult bacterial infections.

Using genomes designed by Evo 2, the team synthesized nearly 300 novel phages and tested them against E. coli. From these, they identified 16 highly effective phages that successfully killed bacteria resistant to naturally occurring phages.

The researchers believe the ability to rapidly design customized phages could transform phage therapy and expand the arsenal against antibiotic-resistant bacteria.

The team redesigned bacteriophage ΦX174, one of the simplest known viruses. Despite its small size, ΦX174 efficiently infects and kills bacteria, making it a valuable model for developing new phage therapies.

A New Weapon Against Antibiotic Resistance

One of the biggest challenges in infectious disease treatment is that bacteria eventually develop resistance to antibiotics—and even to individual phages. To overcome this, the researchers designed a genetically diverse cocktail of 16 AI-created phages.

"If the bacteria gain resistance to a single phage, it's game over for the medication," Hie said. "But if you have multiple genetically distinct phages in a mixture, it would be harder for the bacteria to develop resistance to the entire cocktail."

The team showed that the phage cocktail successfully eliminated E. coli strains that had become resistant to the natural ΦX174 virus.

"We have a proof of concept in the paper, where we show that this cocktail of 16 phages rapidly overcomes resistance in E. coli that is immune to native ΦX174," Hie said.

Potential Beyond E. coli

Researchers believe the same AI-driven approach could eventually be used to develop phages against other drug-resistant bacteria, including:

• Mycobacterium tuberculosis (tuberculosis)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Pseudomonas aeruginosa, a leading cause of antibiotic-resistant hospital-acquired infections

If successful, AI-designed phage cocktails could provide a powerful alternative to conventional antibiotics, whose effectiveness continues to decline because of antimicrobial resistance.

Biosafety Concerns Grow

The researchers have made Evo 2 freely available as open-source software, allowing scientists around the world to design and study new genomes.

While this could accelerate advances in medicine and biotechnology, experts say it also highlights the urgent need for stronger oversight.

"The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not," wrote Prof. Tom Inglesby and Dr. Moritz Hanke of the Center for Health Security at Johns Hopkins University in an accompanying Science commentary.

Tom Ellis, Professor of Synthetic Genome Engineering at Imperial College London, described the research as impressive but cautioned that AI could theoretically be used to design harmful viruses if trained on the genetic code of dangerous pathogens, The Guardian reported.

However, he said safeguards—such as restricting access to sensitive genetic data and screening synthetic genomes before they are manufactured—could help reduce those risks.